RAP-219

N/A

Report date: 2026/05/26 17:00:47
NME

Base Information

Drug NameRAP-219
Drug Alias NameRAP-219
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-dependent calcium channel gamma-8 subunit antagonists
TargetsVoltage-dependent calcium channel gamma-8 subunit
Therapy Area/IndicationsBipolar DisorderBipolar and Related DisordersNeuralgia +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaIND
Originator CompaniesRapport Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTenacia Biotechnology (Hong Kong) Co LtdRapport Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsBipolar DisorderBipolar and Related DisordersNeuralgia +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A